Christoph Lengauer
Co-Founder and CSO @ Curie.Bio
Boston, United States
Christoph Lengauer is a startup investor at Curie.Bio in Boston. Christoph is Co-Founder and CSO at Curie.Bio. Curie.Bio is a founder-focused seed-stage venture firm combined with an industry-grade therapeutics accelerator focused on one thing: helping entrepreneurial founders launch viable therapeutics companies. Curie.Bio does this by giving founders access to a team of the world’s best drug hunters and drugmakers, seed capital, and best-of-breed services - everything a founder needs to get from concept to a compelling dataset that enables an awesome Series A financing. And we do this at scale for 40+ companies / year.Christoph was previously a Venture Partner at Third Rock Ventures, where he helped discover, launch, and build companies based on bold ideas that meet at the intersection of science, strategy, business, and medicine. He was also previously President of Celsius Therapeutics, a startup that develops medicines by understanding the ecosystem of cells using single-cell genomics.In fall of 2015, Christoph was appointed CEO by the German Ministry for Economy to lead the buildout of the German Accelerator Life Sciences (GALS) in Cambridge, MA and Berlin, Germany. GALS provides high-end consulting to emerging German life-science companies and supports them with introducing their products to the US market. In 2017, Christoph founded Advise.Connect.Inspire, which provides similar services to companies across all of Europe.Christoph was also formerly Executive Vice President at Blueprint Medicines (BPMC), where he was the founding CSO and has been leading the clinical progression of BLU-285 until its recent breakthrough therapy designation granted by the FDA for the treatment of patients with unresectable or metastatic PDGFRA D842V mutated gastrointestinal stromal tumors.Christoph has a proven record in drug discovery and contributed to more than 25 drugs that reached human clinical trials as well as four approved lifesaving medicines (Kisqali, Odomzo, Zaltrap, Jevtana). Christoph also worked for approximately ten years at Novartis and as Global Head of Oncology Drug Discovery and Preclinical Development at Sanofi.Prior to joining the pharma/biotech industry, Christoph was an associate professor at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine in Baltimore, MD. Christoph discovered that all cancers are genetically unstable. While co-leading the Vogelstein lab for about a decade, he was involved in the identification of several cancer-driver genes, including BRAF and PIK3CA.Christoph holds adjunct associate professor positions at Johns Hopkins University and Harvard University. A strong and outspoken advocate of patients’ rights, he is featured in the New York Times bestseller and HBO movie, The Immortal Life of Henrietta Lacks.
Last updated:
For AI agents: llms.txt
About Curie.Bio
Curie.Bio is a founder-focused seed-stage venture capital firm.
Curie.Bio Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alexis Borisy
Co-Founder & Chairman
|
|||
Zach Weinberg
Co-Founder and CEO
|
|||
Ben Auspitz
Managing Partner, Breakout Fund
|
|||
|
Christoph Lengauer
Co-Founder and CSO
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
FAQ
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
